3Sbio presses play on $700m Hong Kong IPO
3Sbio started gauging investor interest on Monday for its $700m IPO in Hong Kong, with bankers saying that appetite for the Chinese biotech firm is already looking strong.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts